BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Aloxi
palonosetron HCl injection

Content [1/5/2004]

Binding Affinity

NEW ALOXI™ BINDS STRONG, LASTS LONG.

HIGHLY SELECTIVE FOR THE 5-HT$_3$ RECEPTOR.[1]

- A receptor binding affinity at least 30X higher than any other 5-HT$_3$ receptor antagonist.[†1,2]
- A highly selective 5-HT$_3$ receptor antagonist, with little or no affinity for other receptors.[1,3]

RECEPTOR BINDING AFFINITY[1]



[†]In vitro *data; clinical significance has not been established.*

Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. It should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc. Most commonly reported adverse reactions include headache (9%) and constipation (5%).

References

1. Wong EHF, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT$_3$ receptors, *in vitro*. *Br J Pharmacol.* 1995;114:851-859.
2. Miller RC, Galvan M, Gittos MW, van Giersbergen PLM, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT$_3$ receptors. *Drug Dev Res.* 1993;28:87-93.
3. Aloxi™ (palonosetron HCl) injection full prescribing information.

Distributed and marketed by MGI PHARMA, INC., Bloomington MN 55437
under license of Helsinn Healthcare SA, Switzerland.